Cargando…

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer

Detalles Bibliográficos
Autores principales:	Gulhan, Doga C., Garcia, Elizabeth, Lee, Elizabeth K., Lindemann, Neal I., Liu, Joyce F., Matulonis, Ursula A., Park, Peter J., Konstantinopoulos, Panagiotis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269172/ https://www.ncbi.nlm.nih.gov/pubmed/32494760 http://dx.doi.org/10.1200/PO.20.00009

Ejemplares similares

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Mismatch repair–deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade
por: Sena, Laura A., et al.
Publicado: (2021)

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer
por: Masuda, Kenta, et al.
Publicado: (2011)

Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status
por: Sawada, Kiyoka, et al.
Publicado: (2023)

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report
por: Rey-Cárdenas, Macarena, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands
por: Walker, Romy, et al.
Publicado: (2023)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies
por: Ryan, Neil A. J., et al.
Publicado: (2021)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma
por: Loukovaara, Mikko, et al.
Publicado: (2021)

The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review
por: Favier, Amelia, et al.
Publicado: (2022)

Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer
por: Lubbers, Joyce M., et al.
Publicado: (2022)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022)

Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma
por: ÇAKIR, Emel, et al.
Publicado: (2021)

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
por: Ho, William W., et al.
Publicado: (2021)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
por: Polychronidou, Genovefa, et al.
Publicado: (2018)

MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas
por: Kaneko, Enami, et al.
Publicado: (2021)

The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma
por: Liu, Xiaojuan, et al.
Publicado: (2022)

Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis
por: Jumaah, Alaa Salah, et al.
Publicado: (2021)

Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers
por: Evans, D Gareth, et al.
Publicado: (2022)

Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial Cancer
por: Chaowiwatkun, Kamonporn, et al.
Publicado: (2023)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis
por: Chao, Elizabeth C., et al.
Publicado: (2006)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
por: Antill, Yoland, et al.
Publicado: (2021)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dnlscfhacv50v90jmhv5flduks